Publications & Patents

Lisen Imprinting’s New Technology Eases Fear for HPV-Positive Patients

Lisen Imprinting’s New Technology Eases Fear for HPV-Positive Patients Breakthrough Published in Cancer Communications (IF=20.1): A Novel Early Cervical Cancer Detection Technology Developed by Lisen Imprinting and Sichuan University West China Second University Hospital Wuxi, China – Lisen Imprinting Diagnostics (Wuxi) Co., Ltd. (“Lisen Imprinting”), in collaboration with Sichuan University West China Second University Hospital, has […]

Lisen’s invention patent “MODEL, DIAGNOSTIC METHOD, AND APPLICATION THEREOF” about imprinted gene tumor early diagnosis technology was authorized by the European Patent Office！

Lisen’s invention patent “MODEL, DIAGNOSTIC METHOD, AND APPLICATION THEREOF” about imprinted gene tumor early diagnosis technology was authorized by the European Patent Office on June 22, 2023. Patent number is EP:3633045. The Patent is registered in 17 countries in the Unitary Patent Protection Division, including Germany, France, Italy, Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, Lithuania, Luxembourg, Latvia, Malta, […]

Lisen’s Thyroid Cancer Diagnosis Research Published in the Journal of Clinical Oncology

Lisen announces a revolutionary epigenetics-based diagnostic method for detecting thyroid cancers especially in cytologically indeterminate cases. The clinical research was published in the Journal of Clinical Oncology (JCO), a high-impact, peer-reviewed medical journal of the American Society of Clinical Oncology (ASCO) on November 15. The study leverages Lisen’s QCIGISH (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization) technology which […]

Lisen’s Lung Cancer Diagnosis Research Published in the Clinical Epigenetics Journal

Lisen announces an innovative and ground-breaking epigenetics-based diagnostic solution for early lung cancer detection. The clinical research was published in the Clinical Epigenetics on December 14. The new diagnostic method was based on the QCIGISH (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization) technology developed by Lisen, which can intuitively translate the biallelic and multiallelic expression status of cancer-related […]

Lisen’s QCIGISH Technology Published in the Clinical Epigenetics Journal

Lisen’s methodology paper which innovatively applied visualized epigenetic imprinting biomarkers in the early detection of various cancers has been published in the open access journal Clinical Epigenetics on May 24. Lisen developed and patented the QCIGISH (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization) technology – a novel approach in identifying, visualizing, and quantifying the biallelic and multiallelic expressions […]